

REIMBURSEMENT RESOURCE KIT

VUEWAY® (gadopichlenol) injection for intravenous use

DISCLAIMERS

The information provided here is general reimbursement information for VUEWAY® injection. It is not legal advice, nor is it advice about how to code, complete, or submit any particular claim for payment. Although we supply this information based on our current knowledge, it is always the provider's responsibility to determine and submit appropriate codes, charges, modifiers, and bills for the services that were rendered. This coding and reimbursement information is subject to change without notice. Payers or their local branches may have their own coding and reimbursement requirements and policies. Before filing any claims, providers should verify current requirements and policies with the payer.

CPT® copyright 2025 American Medical Association (AMA). All rights reserved. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.

VUEWAY® (gadopiclenol) injection for intravenous use

Dosage Forms

VUEWAY® is available in single-dose vials, single-dose prefilled syringes, pharmacy bulk packages, and imaging bulk packages.

The VUEWAY Imaging Bulk Package (IBP) is for intravenous use and not for direct infusion. IBP is used for dispensing multiple single doses of gadopiclenol injection for multiple patients, using an automated contrast injection system, or contrast management system approved or cleared for use with this contrast agent in this Imaging Bulk Package. See drug and device labeling for information on devices indicated for use with this Imaging Bulk Package and techniques to help assure safe use.

Indications

VUEWAY injection is indicated in adults and children, including term neonates, for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in:

- the central nervous system (brain, spine, and associated tissues),
- the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).

IMPORTANT SAFETY INFORMATION

WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS

Risk Associated with Intrathecal Use

Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. VUEWAY is not approved for intrathecal use.

NEPHROGENIC SYSTEMIC FIBROSIS

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle, and internal organs.

- **The risk for NSF appears highest among patients with:**
 - Chronic, severe kidney disease ($\text{GFR} < 30 \text{ mL/min/1.73 m}^2$), or
 - Acute kidney injury.
- **Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g., age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.**
- **For patients at highest risk for NSF, do not exceed the recommended VUEWAY dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.**

Contraindications

VUEWAY injection is contraindicated in patients with history of hypersensitivity reactions to VUEWAY.

Warnings and Precautions

There are **risks associated with intrathecal use** of GBCAs that can cause serious adverse reactions including death, coma, encephalopathy, and seizures. The safety and effectiveness of VUEWAY have not been established with intrathecal use and VUEWAY is not approved for intrathecal use.

Risk of **nephrogenic systemic fibrosis** is increased in patients using GBCA agents that have impaired elimination of the drugs, with the highest risk in

patients with chronic, severe kidney disease as well as patients with acute kidney injury. Avoid use of GBCAs among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities.

Hypersensitivity reactions, including serious hypersensitivity reactions, could occur during use or shortly following VUEWAY administration. Assess all patients for any history of a reaction to contrast media, bronchial asthma, and/or allergic disorders, administer VUEWAY only in situations where trained personnel and therapies are promptly available for the treatment of hypersensitivity reactions, and observe patients for signs and symptoms of hypersensitivity reactions after administration.

Gadolinium retention can be for months or years in several organs after administration. The highest concentrations (nanomoles per gram of tissue) have been identified in the bone, followed by other organs (brain, skin, kidney, liver, and spleen). Minimize repetitive GBCA imaging studies, particularly closely spaced studies, when possible.

Acute kidney injury requiring dialysis has occurred with the use of GBCAs in patients with chronically reduced renal function. The risk of acute kidney injury may increase with increasing dose of the contrast agent.

Extravasation and injection site reactions can occur with administration of VUEWAY. Ensure catheter and venous patency before the injection of VUEWAY.

VUEWAY may **impair the visualization of lesions** seen on non-contrast MRI. Therefore, caution should be exercised when VUEWAY MRI scans are interpreted without a companion non-contrast MRI scan.

The most common adverse reactions (incidence $\geq 0.5\%$) are injection site pain (0.7%), and headache (0.7%).

POST-MARKETING EVENTS

The following adverse reactions have been identified during postmarketing use of GBCAs:

- **Gastrointestinal Disorders:** Acute pancreatitis with onset within 48 hours after GBCA administration.
- **General Disorders and Administration Site Conditions:** Fatigue, asthenia, pain syndromes, and heterogeneous clusters of symptoms in the neurological, cutaneous, and musculoskeletal systems with variable onset and duration after GBCA administration.
- **Respiratory, Thoracic and Mediastinal Disorders:** Acute respiratory distress syndrome, pulmonary edema.
- **Skin Disorders:** Gadolinium-associated plaques.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Please click [here](#) for full Prescribing Information for VUEWAY (gadopiclenol) injection for intravenous use including BOXED WARNING on Nephrogenic Systemic Fibrosis.

Manufactured for Bracco Diagnostics Inc. by BIPSO GmbH, 78224 Singen (Germany).

VUEWAY is a registered trademark of Bracco Imaging S.p.A.

All other trademarks and registered trademarks are the property of their respective owners.

No Compromise in MRI	4
CPT Coding Charts	5-7
Coding Nomenclature	8
Coding Information	9
Example of Billing.....	11
Hospital In-Patient Billing and Coverage.....	13
Ordering Information.....	14
Reimbursement Hotline.....	15
References	16

Consider the product attributes of **VUEWAY® (gadopichlenol) injection** for intravenous use

For MRI, choose the low-dose contrast agent with the highest relaxivity:

VUEWAY injection, a unique macrocyclic gadolinium-based contrast agent (GBCA).^{1,6,7}

A LOW GADOLINIUM DOSE

compared to all
the GBCAs approved
at 0.1 mmol Gd/kg¹⁻⁵

Gadopichlenol:
the highest
RELAXIVITY
of all GBCAs today^{6,7}

ACR GROUP II AGENT*

Gadopichlenol is classified
by the American College
of Radiology as a
Group II agent*

EXTENSIVE SAFETY DATA

882,550 administrations in
the U.S. from February 2023
to March 2024 reported no
serious adverse events⁸

GENERAL-USE GBCA

approved across a range
of indications for multiple
areas of the body and CNS
in patients of all ages,
including neonates¹

*Group II agents are associated with few, if any, unconfounded cases of NSF.⁹

MRA CPT CODING CHART¹⁰

ORBIT, FACE & NECK

70540 - Without contrast
70542 - With contrast
70543 - With & without contrast

BRAIN

70551 - Without contrast
70552 - With contrast
70553 - With & without contrast

TMJ

70336

THORACIC SPINE

72146 - Without contrast
72147 - With contrast
72157 - With & without contrast

CERVICAL SPINE

72141 - Without contrast
72142 - With contrast
72156 - With & without contrast

FETAL IMAGING

(Single or first gestation)

74712

FETAL IMAGING

(Each additional gestation)

74713

SHOULDER, ELBOW, OR WRIST

(Upper Extremity, Joint)

73221 - Without contrast
73222 - With contrast
73223 - With & without contrast

HUMERUS, FOREARM, AND/OR HAND

(Upper Extremity, Non-Joint)

73218 - Without contrast
73219 - With contrast
73220 - With & without contrast

HIP, KNEE, AND/OR ANKLE

(Lower Extremity, Joint)

73721 - Without contrast
73722 - With contrast
73723 - With & without contrast

THIGH, LOWER LEG, AND/OR FOOT

(Lower Extremity, Non-Joint)

73718 - Without contrast
73719 - With contrast
73720 - With & without contrast

CARDIAC FOR MORPHOLOGY & FUNCTION

75557 - Without contrast
75559 - Without contrast, with stress imaging
75561 - Without contrast, followed by contrast and further sequences
75563 - Without contrast, followed by contrast and further sequences; with stress imaging

CARDIAC FOR VELOCITY FLOW MAPPING

75565

CHEST

71550 - Without contrast
71551 - With contrast
71552 - With & without contrast

BREAST

77046 - Without contrast; unilateral
77047 - Without contrast; bilateral
77048 - With & without contrast; including CAD; unilateral
77049 - With & without contrast; including CAD; bilateral

ABDOMEN

74181 - Without contrast
74182 - With contrast
74183 - With & without contrast

LUMBAR SPINE

72148 - Without contrast
72149 - With contrast
72158 - With & without contrast

PELVIS

72195 - Without contrast
72196 - With contrast
72197 - With & without contrast

MRI

MRA CPT CODING CHART¹⁰

NECK

70547 - Without contrast
70548 - With contrast
70549 - With & without contrast

HEAD

70544 - Without contrast
70545 - With contrast
70546 - With & without contrast

SPINAL CANAL AND CONTENTS

72159 - With or without contrast

CHEST

71555 - With or without contrast

UPPER EXTREMITY

73225 - With or without contrast

ABDOMEN

74185 - With or without contrast

LOWER EXTREMITY

73725 - With or without contrast

PELVIS

72198 - With or without contrast

MRA

CPT CODING CHART

C Codes¹¹

C Codes are created by Medicare for Patients under HOPPS. In some circumstances, commercial payors may accept these codes in non-hospital settings.

C8900	MRA w/ contrast, abdomen
C8902	MRA w/o followed by w/ contrast, abdomen
C8905	MRI w/o followed by w/ contrast, breast, unilateral
C8906	MRI w/ contrast, breast, bilateral
C8908	MRI w/o fol w/ contrast, breast
C8909	MRA w/ contrast, chest
C8911	MRA w/o fol w/ contrast, chest
C8912	MRA w/ contrast, lower extremity
C8914	MRA w/o contrast fol w/ contrast, lower extremity
C8918	MRA w/ contrast, pelvis
C8920	MRA w/o fol w/ contrast, pelvis
C8931	MRA, w/ contrast, spinal canal
C8933	MRA, w/o & w/ contrast, spinal canal
C8934	MRA, w/ contrast, upper extremity
C8937	MRI, CAD, breast (list separately in addition to code for primary procedure)

CPT® (Current Procedural Terminology)

Codes used to report the service or procedure performed.

HCPCS (Healthcare Common Procedure Coding System)

Codes used to report the provision of supplies, materials, injections, and certain services and procedures. For example, the HCPCS code for VUEWAY® (gadopiclenol) injection for intravenous use is A9573, Injection, gadopiclenol, 1 mL.

Coding Modifiers

Under HOPPS, VUEWAY injection is not separately reimbursable, and therefore the JZ and JW Modifiers do not apply under this billing system. They are required for independent imaging centers billing under the Medicare Physician Fee Schedule.

ICD-10-CM (International Classification of Disease)

Codes used to describe a patient's signs and symptoms that would represent a medically necessary reason for performing the procedure. ICD-10-CM codes need to be entered on the claim form. ICD-10-CM is the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD), a medical classification list by the World Health Organization (WHO).

APC (Ambulatory Payment Classification)

In most cases, the unit of payment under the HOPPS is the APC. CMS assigns individual services HCPCS & CPT codes to APCs based on similar clinical characteristics and similar costs. The payment rate and copayment calculated for an APC apply to each service within the APC.

NDC (National Drug Code)

An NDC code provides a unique identifier for a specific drug. NDCs for VUEWAY injection are on page 14.

Medicare Addendum B

These files are updated quarterly and reflect HOPPS payment rates for HCPCS codes and APC codes.

<https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/addendum-a-b-updates>.

Medicare Part B ASP (average selling price) file

Quarterly payment files are published for Independent Diagnostic Testing Facilities (IDTFs) and physician offices. This is where the payment value for VUEWAY injection (A9573, Injection, gadopiclenol, 1 mL) can be found:

<https://www.cms.gov/medicare/payment/all-fee-service-providers/medicare-part-b-drug-average-sales-price/asp-pricing-files>.

Medicare Physician Fee Schedule (MPFS)

Find out physician payment for specific geographic locations in the country for different procedures. This schedule provides: global (G), technical (TC), and professional (26) component payment rates. To find out more information on specific locations visit:

<https://www.cms.gov/medicare/physician-fee-schedule/search/overview>.

VUEWAY[®] (gadopichlenol) injection for intravenous use HCPCS Code¹²: A9573, Injection, gadopichlenol, 1 mL

Medicare Patients: VUEWAY injection is part of a bundled payment under HOPPS and not separately reimbursed. Please code separately with the echocardiography and radiology procedure codes.

Commercially insured patients: The provider must contact their respective insurance providers to include A9573 and establish a reimbursement value.

Medicaid Patients: Medicaid coverage varies by state, please consult your local Medicaid office to find the policies in your area. Bracco does not participate in the Medicaid Rebate Program.

Procedure Codes: Contrast enhanced MRI CPT codes are part of the 70000 series codes. Please refer to the American Medical Association's official CPT book for a complete list.



Volume of VUEWAY® (gadopiclenol) injection for intravenous use by Body Weight

For patients <22 lbs (10 kg) the dose of VUEWAY injection is calculated using 0.1 mL/kg

BODY WEIGHT		VOLUME
Pounds (lb)	Kilograms (kg)	Milliliters (mL)
22	10	1
44	20	2
66	30	3
88	40	4
110	50	5
132	60	6
154	70	7
176	80	8
198	90	9
220	100	10
242	110	11
264	120	12
286	130	13
308	140	14
330	150	15

For patients >330 lbs (150 kg) the dose of VUEWAY injection is calculated using 0.1 mL/kg

Sample hospital setting billing form UB-04 CMS-1450
Contrast enhanced MRI

[illegible]

Sample health insurance claim form CMS-1500

HEALTH INSURANCE CLAIM FORM

APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

☐ PICA												☐ PICA																																			
1. MEDICARE ☐ MEDICAID ☐ TRICARE ☐ CHAMPVA ☐ GROUP HEALTH PLAN ☐ FECA OR LUNG ☐ OTHER ☐ (Medicare#) (Medicaid#) (ID#/DoD#) (Member ID#) (ID#) (ID#)												1a. INSURED'S I.D. NUMBER (For Program in Item 1)																																			
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)												3. PATIENT'S BIRTH DATE MM DD YY SEX M ☐ F ☐												4. INSURED'S NAME (Last Name, First Name, Middle Initial)																							
5. PATIENT'S ADDRESS (No., Street)												6. PATIENT RELATIONSHIP TO INSURED Self ☐ Spouse ☐ Child ☐ Other ☐												7. INSURED'S ADDRESS (No., Street)																							
CITY STATE												8. RESERVED FOR NUCC USE												CITY STATE																							
ZIP CODE TELEPHONE (Include Area Code) ()												9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)												10. IS PATIENT'S CONDITION RELATED TO: a. EMPLOYMENT? (Current or Previous) ☐ YES ☐ NO b. AUTO ACCIDENT? ☐ YES ☐ NO PLACE (State) ☐ c. OTHER ACCIDENT? ☐ YES ☐ NO 10d. CLAIM CODES (Designated by NUCC)												11. INSURED'S POLICY GROUP OR FECA NUMBER a. INSURED'S DATE OF BIRTH MM DD YY SEX M ☐ F ☐ b. OTHER CLAIM ID (Designated by NUCC) c. INSURANCE PLAN NAME OR PROGRAM NAME d. IS THERE ANOTHER HEALTH BENEFIT PLAN? ☐ YES ☐ NO If yes, complete Items 9, 9a, and 9d.											
12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.												13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE I authorize payment of medical benefits to the undersigned physician or supplier for services described below.																																			
24D. (HCPCS/Rates/HIPPS Code)												16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY												18. HOSPITALIZATION DATES RELATED TO THIS CLAIM FROM MM DD YY TO MM DD YY																							
HCPCS code for procedure and material												17a. NPI												20. OUTSIDE LAB? ☐ YES ☐ NO																							
Enhanced MRI (gadopiclenol) solution for 0.5 mg/mL												17b. NPI												22. RESUBMISSION CODE																							
Discarded drug and waste												17c. NPI												23. PRIOR AUTHORIZATION NUMBER																							
Discarded drug and waste												17d. NPI												24. A. DATE(S) OF SERVICE From MM DD YY To MM DD YY B. PLACE OF SERVICE C. EMG D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) CPT/HCPCS MODIFIER E. DIAGNOSIS POINTER F. \$ CHARGES G. DAYS OR UNITS H. EPID/Infusion Plan I. ID. QUAL J. RENDERING PROVIDER ID. #																							
1. 05 01 26 05 01 26 70552												2. 05 01 26 05 01 26 A9573 8 mL												3. 05 01 26 05 01 26 A9573 JW 2 mL																							
4. 05 01 26 05 01 26 A9573												5. 05 01 26 05 01 26 A9573												6. 05 01 26 05 01 26 A9573																							
7. 05 01 26 05 01 26 A9573												8. 05 01 26 05 01 26 A9573												9. 05 01 26 05 01 26 A9573																							
10. 05 01 26 05 01 26 A9573												11. 05 01 26 05 01 26 A9573												12. 05 01 26 05 01 26 A9573																							
13. 05 01 26 05 01 26 A9573												14. 05 01 26 05 01 26 A9573												15. 05 01 26 05 01 26 A9573																							
16. 05 01 26 05 01 26 A9573												17. 05 01 26 05 01 26 A9573												18. 05 01 26 05 01 26 A9573																							
19. 05 01 26 05 01 26 A9573												20. 05 01 26 05 01 26 A9573												21. 05 01 26 05 01 26 A9573																							
22. 05 01 26 05 01 26 A9573												23. 05 01 26 05 01 26 A9573												24. 05 01 26 05 01 26 A9573																							
25. 05 01 26 05 01 26 A9573												26. 05 01 26 05 01 26 A9573												27. 05 01 26 05 01 26 A9573																							
28. 05 01 26 05 01 26 A9573												29. 05 01 26 05 01 26 A9573												30. 05 01 26 05 01 26 A9573																							
31. 05 01 26 05 01 26 A9573												32. 05 01 26 05 01 26 A9573												33. 05 01 26 05 01 26 A9573																							
34. 05 01 26 05 01 26 A9573												35. 05 01 26 05 01 26 A9573												36. 05 01 26 05 01 26 A9573																							
37. 05 01 26 05 01 26 A9573												38. 05 01 26 05 01 26 A9573												39. 05 01 26 05 01 26 A9573																							
39. 05 01 26 05 01 26 A9573												40. 05 01 26 05 01 26 A9573												41. 05 01 26 05 01 26 A9573																							
42. 05 01 26 05 01 26 A9573												43. 05 01 26 05 01 26 A9573												44. 05 01 26 05 01 26 A9573																							
45. 05 01 26 05 01 26 A9573												46. 05 01 26 05 01 26 A9573												47. 05 01 26 05 01 26 A9573																							
48. 05 01 26 05 01 26 A9573												49. 05 01 26 05 01 26 A9573												50. 05 01 26 05 01 26 A9573																							
51. 05 01 26 05 01 26 A9573												52. 05 01 26 05 01 26 A9573												53. 05 01 26 05 01 26 A9573																							
54. 05 01 26 05 01 26 A9573												55. 05 01 26 05 01 26 A9573												56. 05 01 26 05 01 26 A9573																							
57. 05 01 26 05 01 26 A9573												58. 05 01 26 05 01 26 A9573												59. 05 01 26 05 01 26 A9573																							
60. 05 01 26 05 01 26 A9573												61. 05 01 26 05 01 26 A9573												62. 05 01 26 05 01 26 A9573																							
63. 05 01 26 05 01 26 A9573												64. 05 01 26 05 01 26 A9573												65. 05 01 26 05 01 26 A9573																							
66. 05 01 26 05 01 26 A9573												67. 05 01 26 05 01 26 A9573												68. 05 01 26 05 01 26 A9573																							
69. 05 01 26 05 01 26 A9573												70. 05 01 26 05 01 26 A9573												71. 05 01 26 05 01 26 A9573																							
72. 05 01 26 05 01 26 A9573												73. 05 01 26 05 01 26 A9573												74. 05 01 26 05 01 26 A9573																							
75. 05 01 26 05 0																																															

Hospital in-patient billing: Medicare Severity Adjusted Diagnosis Related Groups (MS-DRG)¹³

ICD-10-PCS procedure codes are used for in-patient billing. They indicate the surgical and/or diagnostic procedures performed on the patient. These codes, in combination with diagnosis codes, help determine the assignment to an MS-DRG payment category under Medicare and other payment systems. Payment in the hospital is determined by the MS-DRG. Under this system, a hospital is paid at a predetermined specific rate for each Medicare discharge. Fixed reimbursement is established for hospital services based on the patient diagnosis and is paid regardless of the actual cost the hospital incurs in providing the services. MRI exams and contrast agents are part of the MS-DRG payment.

Coverage: Medicare National Coverage Decisions (NCD)

Though CMS covers MRIs for different parts of the body for many different indications, it is important to remember to only perform the exam when it is necessary.

Title XVIII of the Social Security Act (SSA), §1862(a)(1)(A) states that no Medicare payment shall be made for items or services that “are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.”

For more coverage information, please visit the Medicare Coverage Database search tool at:

<https://www.cms.gov/medicare-coverage-database/search.aspx>.

How to Order VUEWAY[®] (gadopichlenol) injection for intravenous use

VIAL (GLASS)			
	Count	SKU	NDC
3 mL vial (filled in 10 mL vial)	10	702038	0270-7020-38
7.5 mL vial (filled in 10 mL vial)	10	702540	0270-7025-40
10 mL vial (filled in 10 mL vial)	10	703042	0270-7030-42

IMAGING BULK PACKAGE			
	Count	SKU	NDC
30 mL vial (filled in 50 mL vial)	10	701575	0270-7015-75
50 mL vial (filled in 50 mL vial)	10	701576	0270-7015-76

Please Note: For billing purposes, an extra 0 should be added to the beginning of the NDC number.

To order, call Bracco Customer Service at
1-877-BRACCO-9 (1-877-272-2269), option 2
or visit us online at:
MyOrders.Bracco.com



How we support you

The Bracco Reimbursement Hotline is here to support you for all your reimbursement needs.

Ask coding and billing questions regarding Bracco Diagnostics products and procedures related to those products.

- ✓ HCPCS codes for products
- ✓ CPT® and HCPCS codes for procedures
- ✓ Medicare payments
- ✓ Monday-Friday: 9:00 AM-6:00 PM Eastern Time

For more information on reimbursement, contact the Bracco Reimbursement Hotline at:



1-800-349-1388




askbracco@reimbursement.bracco.com

Please visit us at www.braccoreimbursement.com for more information

On our website, you may sign up to:

- ✓ Receive educational emails
- ✓ Access our complimentary reimbursement webinars
- ✓ Get the latest updates on:
 - Coding
 - Coverage
 - Payment



1. VUEWAY® (gadopiclenol) injection for intravenous use Full Prescribing Information and Patient Medication Guide. Princeton, NJ: Bracco Diagnostics Inc.; February 2026.
2. GADAVIST® (gadobutrol) Injection. Full Prescribing Information. Bayer HealthCare Pharmaceuticals Inc. Whippany, NJ; March 2025.
3. DOTAREM® (gadoterate meglumine) Injection. Full Prescribing Information. Guerbet LLC. Princeton, NJ; March 2025.
4. CLARISCAN™ (gadoterate meglumine) injection for intravenous use. Full Prescribing Information. GE Healthcare. Chicago, IL; November 2020.
5. ProHance® (Gadoteridol) Injection, 279.3 mg/mL Full Prescribing Information and Patient Medication Guide. Princeton, NJ: Bracco Diagnostics Inc.; March 2025.
6. Robic C, Port M, Rousseaux O, et al. Physicochemical and pharmacokinetic profiles of gadopiclenol: a new macrocyclic gadolinium chelate with high T1 relaxivity. *Invest Radiol.* 2019 Aug;54:475-484.
7. Lohrke J, Berger M, Frenzel T, et al. Preclinical profile of gadoquatran: a novel tetrameric, macrocyclic high relaxivity gadolinium-based contrast agent. *Invest Radiol.* 2022 Oct 1;57(10):629-638.
8. Spinazzi A, Lancelot E, Vitali L, et al. Safety of gadopiclenol after its first year of clinical use. *Invest Radiol.* ():10.1097/RLI.0000000000001144, November 21, 2024. | DOI: 10.1097/RLI.0000000000001144
9. American College of Radiology. *ACR Manual on Contrast Media*. Updated 2025. <https://www.acr.org/clinical-resources/clinical-tools-and-reference/contrast-manual>. Accessed May 2026, 2026.
10. *2026 Professional Edition CPT® Current Procedural Terminology*. American Medical Association. Chicago, IL; 2025.
11. Centers for Medicare & Medicaid Services. HCPCS Quarterly Update: October 2023 Alpha-Numeric HCPCS Files. <https://www.cms.gov/medicare/coding/hcpcsreleasecodesets/hcpcs-quarterly-update.pdf>. Accessed May 26, 2026.
12. Centers for Medicare & Medicaid Services (CMS) healthcare common procedure coding system (HCPCS) application summaries and coding recommendations. Centers for Medicare & Medicaid Services. <https://www.cms.gov/Medicare/Coding/MedHCPCSGenInfo/Prior-Years-CMS-HCPCS-LevelIII-Coding-Decisions-Narrative-Summary.pdf>. Accessed May 26, 2026.
13. Centers for Medicare & Medicaid Services. Medicare Claims Processing Manual. Washington, DC: Centers for Medicare & Medicaid Services, Department of Health and Human Services. Published December 2022. <https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c03.pdf>. Accessed May 26, 2026.

Bracco Diagnostics Inc.
510 Carnegie Center
Suite 300
Princeton, NJ 08540 USA
Phone: 609-514-2200
Toll-Free: 1-800-631-5245 (U.S. only)
Fax: 609-514-2424

© 2026 Bracco Diagnostics Inc. All Rights Reserved. US-VW-2300031 07/26